Phase 1 Study of LNK001 in Advanced Clear Cell Renal Cell Carcinoma Initiated
A Phase 1 study of LNK001 is underway to determine the recommended dose and efficacy in advanced ccRCC.
Asset / Drug
Drug and asset intelligence for LNK001 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.